Logo

CCEL

Cryo-Cell International, Inc.

CCEL

Cryo-Cell International, Inc. • NASDAQ
$4.30 ▲ 5.91% (+0.24)
Market Cap $34.63 M
52w High $8.86
52w Low $4.00
Dividend Yield 0.40%
P/E -71.67
Volume 753
Outstanding Shares 8.05M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $7.825M ▼ $4.123M ▼ $1.623M ▲ 20.735% ▲ $0.09 ▲ $1.91M ▲
Q2-2025 $7.929M ▼ $4.58M ▼ $355.785K ▲ 4.487% ▲ $0.04 ▲ $1.624M ▲
Q1-2025 $7.969M ▼ $4.928M ▼ $282.855K ▲ 3.549% ▲ $0.03 ▲ $1.369M ▲
Q4-2024 $8.024M ▼ $6.51M ▲ $-1.862M ▼ -23.2% ▼ $-0.23 ▼ $242.502K ▲
Q3-2024 $8.067M $4.551M $1.052M 13.037% $0.13 $-2.022M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $3.221M ▼ $63.169M ▼ $78.001M ▼ $-14.831M ▲
Q2-2025 $4.431M ▲ $64.438M ▲ $79.998M ▲ $-15.56M ▼
Q1-2025 $3.479M ▼ $64.381M ▼ $79.037M ▲ $-14.656M ▼
Q4-2024 $3.496M ▲ $64.678M ▲ $77.894M ▲ $-13.216M ▼
Q3-2024 $2.127M $62.934M $72.493M $-9.559M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $749.408K ▲ $2.537M ▲ $1.105M ▲ $-3.514M ▼ $127.716K ▲ $2.498M ▲
Q2-2025 $355.785K ▲ $707.014K ▼ $-1.503M ▼ $710.155K ▲ $-85.631K ▲ $644.606K ▼
Q1-2025 $282.855K ▲ $954.063K ▼ $-287.484K ▲ $-1.004M ▼ $-337.838K ▼ $892.01K ▼
Q4-2024 $-1.862M ▼ $2.157M ▼ $-1.116M ▼ $-677.821K ▲ $363.523K ▲ $2.015M ▼
Q3-2024 $1.052M $2.437M $-665.603K $-2.043M $-271.758K $2.118M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
Processing And Storage Fees
Processing And Storage Fees
 $10.00M ▲$10.00M ▲$10.00M ▲$10.00M ▲
Product
Product
 $0 ▲$0 ▲$0 ▲$0 ▲
Public Banking
Public Banking
 $0 ▲$0 ▲$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Revenue has been very steady over the past five years, with no real signs of strong growth but also no major drops. Profitability is thin and has hovered around break-even, with one clearly loss-making year recently followed by a return to a small profit. This pattern suggests a mature core business that is stable but not yet scaling quickly. Earnings per share have been quite volatile relative to the small level of profits, likely reflecting one-off items or a small share base, which can make the headline figures look more dramatic than the underlying business trend really is.

Balance Sheet

Balance Sheet The balance sheet is modest in size and relatively stable, but it shows some pressure points. Total assets have been fairly steady, yet cash has drifted down from earlier years, which reduces the short-term cushion. Debt levels are not large in absolute terms but matter more in the context of a small asset base and very thin profits. Shareholders’ equity has slipped slightly into negative territory, which can signal accumulated past losses or write-downs and leaves the company with limited balance sheet flexibility. Overall, the company looks financially lean, with little room for prolonged setbacks without fresh capital or improved profitability.

Cash Flow

Cash Flow Despite the thin profits, the business has consistently generated positive cash from operations, which is a key strength. This operating cash has generally been enough to cover day-to-day needs and a modest level of investment. Free cash flow has hovered around break-even, occasionally dipping slightly negative when capital spending stepped up, likely tied to facilities and technology upgrades. The pattern suggests a company that can fund its basic operations internally but may need either stronger earnings or external funding to comfortably support larger growth projects over time.

Competitive Edge

Competitive Edge Cryo-Cell occupies a differentiated niche in healthcare as a pioneer in private cord blood banking, with decades of experience and a long-standing brand. Its quality credentials, including multiple respected accreditations and regulatory compliance, help build trust in a field where safety and reliability are critical. Exclusive rights to certain processing technologies and patents, especially around cord blood and menstrual stem cells, add a technical edge. The partnership with Duke University further strengthens its scientific reputation and gives it access to advanced clinical know-how. Its recurring revenue model from storage fees provides a stable base, but the company still operates in a competitive, specialized market where other private banks and public programs vie for the same families and hospital relationships.

Innovation and R&D

Innovation and R&D Innovation is a core part of Cryo-Cell’s story. It has invested in specialized processing and storage technologies that aim to increase the usefulness and flexibility of stored stem cells, such as improved processing methods and multi-compartment storage bags. It has also moved into areas like menstrual stem cells and additional tissue types, widening its potential role in regenerative medicine. The collaboration with Duke University is central: Cryo-Cell holds rights to certain clinical protocols and data, and is working toward offering actual cellular therapies, not just storage. The planned spin-off of Celle Corp., the new facility in Durham, and initiatives like ExtraVault and future infusion clinics all signal an ambition to evolve from a storage company into a broader cell-therapy platform. However, success depends heavily on clinical trial outcomes, regulatory approvals, and the company’s ability to execute on complex healthcare operations, all of which carry significant uncertainty.

Summary

Cryo-Cell is a small, specialized healthcare company with a stable but low-growth revenue base built on cord blood and related stem cell banking. Its profits are modest and occasionally slip into losses, and its balance sheet is thin, with limited cash, some debt, and slightly negative equity, which heightens sensitivity to operational missteps or delays. On the positive side, the business generates steady operating cash, enjoys recurring revenue from long-term storage contracts, and holds a credible competitive position built on first-mover status, quality accreditations, and exclusive technologies. The real upside potential lies in its strategic shift toward cellular therapies, backed by its Duke University collaboration, new facilities, and pipeline of planned services. At the same time, that shift increases reliance on scientific, regulatory, and execution outcomes that are inherently uncertain. Overall, Cryo-Cell appears to be at a turning point: a stable, niche banking business attempting a transition into a more ambitious but riskier therapeutic model.

NEWS

October 15, 2025 · 5:00 PM UTC

Cord Blood Banking Leader Cryo-Cell Reports Fiscal Third Quarter 2025 Financial Results

Read more